A study conducted by researchers at Karolinska Institutet demonstrates that analyzing the genes within breast cancer tumors can predict which patients will not benefit from chemotherapy prior to surgery. Published in Nature Communications, the findings suggest a pathway toward more personalized treatment strategies for hormone-dependent, HER2-negative breast cancer. The research involved 179 participants from the Swedish PREDIX LumB trial. These patients received both chemotherapy and a combination of hormone-blocking therapy and palbociclib, a drug that inhibits cancer cell division, but in different sequences. Some patients started with chemotherapy followed by the drug combination, while others began with the drug combination followed by chemotherapy. The overall results showed that both treatment sequences led to similar reductions in tumor size and equivalent survival rates. However, detailed analysis revealed a specific subgroup of tumors that responded poorly to chemotherapy but showed a better response to the combination of palbociclib and hormone-blocking therapy. To understand the biological reasons behind these varying responses, the team analyzed gene expression patterns in tumor tissue samples collected before treatment began. This allowed them to identify which genes were active in the tumor. Based on this data, the researchers developed a predictive model known as CDKPredX. This model analyzes patterns of gene expression, including genes related to cell division, hormone signaling, and the immune system, to identify tumors that are likely to resist chemotherapy but respond well to the alternative therapy. When the researchers tested CDKPredX on other patient groups, they observed consistent predictive patterns. Alexios Matikas, the study's first author and a docent at the Department of Oncology-Pathology, noted that reliable methods to predict pre-surgical chemotherapy benefits have previously been lacking. He stated that tumor gene expression can provide crucial information in this area. Theodoros Foukakis, the senior author and professor, added that while the goal is to help patients avoid ineffective treatments like chemotherapy and receive more successful alternatives, the method is not yet ready for routine clinical use. The researchers emphasize that the study is exploratory. While the results offer significant new insights into why different tumors react differently to specific treatments, further studies are required before the genetic analysis can be implemented in standard clinical practice. If successful, this approach could significantly reduce unnecessary toxicity for patients by tailoring therapy to the genetic profile of their specific tumor.